Related references
Note: Only part of the references are listed.Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya
Gaudensia Mutua et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
Zacchaeus Anywaine et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?
Michelle Meyer et al.
TRENDS IN MICROBIOLOGY (2019)
Adaptive NK cells in people exposed to Plasmodium falciparum correlate with protection from malaria
Geoffrey T. Hart et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways
Sinthujan Jegaskanda et al.
JOURNAL OF VIROLOGY (2019)
A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model
Rohan Kesbwara et al.
JOURNAL OF VIROLOGY (2019)
Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells
Katja Srpan et al.
JOURNAL OF CELL BIOLOGY (2018)
A novel Ebola virus antibody-dependent cell-mediated cytotoxicity (Ebola ADCC) assay
Karnail Singh et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2018)
IL-15 Promotes Polyfunctional NK Cell Responses to Influenza by Boosting IL-12 Production
Helen R. Wagstaffe et al.
JOURNAL OF IMMUNOLOGY (2018)
Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection
Erica Ollmann Saphire et al.
CELL (2018)
A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus
Bronwyn M. Gunn et al.
CELL HOST & MICROBE (2018)
Antibody-mediated protection against Ebola virus
Erica Ollmann Saphire et al.
NATURE IMMUNOLOGY (2018)
CMV and natural killer cells: shaping the response to vaccination
Martin R. Goodier et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2018)
Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year
Rebecca L. Winslow et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Antibody-dependent-cellular-cytotoxicity- inducing antibodies significantly affect the post-LEexposure treatment of Ebola virus infection
Qiang Liu et al.
SCIENTIFIC REPORTS (2017)
Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
Anne Rechtien et al.
CELL REPORTS (2017)
Enhancement of cytokine-driven NK cell IFN-γ production after vaccination of HCMV infected Africans
Alansana Darboe et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects
Wataru Oboshi et al.
HUMAN IMMUNOLOGY (2016)
Safety and Immunogenicity of Novel Adenovirus Type 26-and Modified Vaccinia Ankara-Vectored Ebola Vaccines A Randomized Clinical Trial
Iain D. Milligan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection
David J. DiLillo et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Dimeric FcγR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG
Bruce D. Wines et al.
JOURNAL OF IMMUNOLOGY (2016)
Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge
Sinthujan Jegaskanda et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody
Davide Corti et al.
SCIENCE (2016)
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
Caroline Jochems et al.
ONCOTARGET (2016)
Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection
Andrea Marzi et al.
SCIENTIFIC REPORTS (2016)
Sustained Immune Complex-Mediated Reduction in CD16 Expression after Vaccination Regulates NK Cell Function
Martin R. Goodier et al.
FRONTIERS IN IMMUNOLOGY (2016)
Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function
Heinrich Schlums et al.
IMMUNITY (2015)
Impaired NK Cell Responses to Pertussis and H1N1 Influenza Vaccine Antigens in Human Cytomegalovirus-Infected Individuals
Carolyn M. Nielsen et al.
JOURNAL OF IMMUNOLOGY (2015)
The pathogenesis of human cytomegalovirus
Paul Griffiths et al.
JOURNAL OF PATHOLOGY (2015)
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Xiangguo Qiu et al.
NATURE (2014)
Human Cytomegalovirus Drives Epigenetic Imprinting of the IFNG Locus in NKG2Chi Natural Killer Cells
Merlin Luetke-Eversloh et al.
PLOS PATHOGENS (2014)
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
Rizwan Romee et al.
BLOOD (2013)
Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine
Joseph E. Blaney et al.
PLOS PATHOGENS (2013)
Properties of mouse and human IgG receptors and their contribution to disease models
Pierre Bruhns
BLOOD (2012)
Antigenic Subversion: A Novel Mechanism of Host Immune Evasion by Ebola Virus
Gopi S. Mohan et al.
PLOS PATHOGENS (2012)
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge
Kelly L. Warfield et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Julie A. Bowles et al.
BLOOD (2006)
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
